Risk Assessment and Management of Drug-Induced Liver Injury with Multiple Antimicrobials

Risk Factors and Assessment

Multiple antimicrobial agents significantly increase the risk of DILI through various mechanisms including direct hepatotoxicity, idiosyncratic reactions, and immune-mediated injury 1, 3
Worsening liver function tests in a patient on multiple antimicrobials strongly suggests drug-induced liver injury, especially when other causes have been excluded 4, 5
The risk is compounded by polypharmacy with five antimicrobials, increasing the likelihood of drug interactions and cumulative hepatotoxicity 2
Pre-existing liver dysfunction reduces drug metabolism capacity and increases vulnerability to further injury 6, 7

Ceftazidime-avibactam (Zavicefta) carries a moderate risk of transaminase elevations, typically transient but can be significant in patients with baseline liver dysfunction 5

Immediately assess the pattern and severity of liver enzyme elevation to guide management decisions 8, 5
For ALT/AST >3× ULN or a doubling of baseline values in patients with pre-existing liver dysfunction, consider discontinuation of the most hepatotoxic agents (colistin first, followed by teicoplanin) 4, 9
For severe elevations (ALT/AST >5× ULN) or any elevation with symptoms, discontinue all potentially hepatotoxic medications if clinically feasible 8, 9
Monitor liver function tests every 1-3 days until improvement is noted, then weekly until normalization 5, 9

Perform comprehensive liver function tests including ALT, AST, alkaline phosphatase, GGT, bilirubin (total and direct), and INR 10, 5
Evaluate for signs of hepatic decompensation (encephalopathy, coagulopathy, ascites) 6, 7
Consider abdominal ultrasound to exclude other causes of liver dysfunction and assess for signs of advanced liver disease 10, 9

DILI can progress despite discontinuation of the offending drugs, requiring continued vigilance 4
Patients with pre-existing liver disease are at higher risk for severe outcomes from DILI, including progression to liver failure 6, 7
Rechallenge with suspected hepatotoxic agents should be avoided unless absolutely necessary for life-threatening infections with no alternatives 3, 9